Dr Moorman's highlights on mixed phenotype acute leukemia (MPAL) from ASH 2016
What’s new in minimal residual disease (MRD) detection in myeloma?
The aims of the Genomics England CLL pilot
Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma
Bruno Paiva et al.
Subcutaneous rituximab versus intravenous rituximab – safety and efficacy results